{
    "root": "cd9bea2a-6045-452d-9ac5-e70d08e9e26f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "zoledronic acid",
    "value": "20250311",
    "ingredients": [
        {
            "name": "zoledronic acid",
            "code": "6XC1PAD3KF"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "mannitol",
            "code": "3OWL53L36A"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        },
        {
            "name": "sodium citrate",
            "code": "1Q73Q2JULR"
        }
    ],
    "indications": "zoledronic acid injection bisphosphonate indicated treatment : hypercalcemia malignancy . ( 1.1 ) patients multiple myeloma patients documented bone metastases solid tumors , conjunction standard antineoplastic therapy . prostate cancer progressed treatment least one hormonal therapy . ( 1.2 ) limitations : safety efficacy zoledronic acid injection established hyperparathyroidism non-tumor-related hypercalcemia .",
    "contraindications": "parenteral products inspected visually particulate matter discoloration prior , whenever solution container permit .",
    "warningsAndPrecautions": "zoledronic acid injection supplied follows : ndc zoledronic acid injection ( 0.04 mg per ml ) package factor 25021-826-82 4 mg per 100 ml single-dose bag 1 bag per carton 25021-826-87 4 mg per 100 ml single-dose bag 5 bags per carton",
    "adverseReactions": "hypersensitivity including cases urticaria angioedema , cases anaphylactic reaction/shock reported [ ( 6.2 ) ] .",
    "indications_original": "Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. ( 1.1 ) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of Use : The safety and efficacy of Zoledronic Acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.",
    "contraindications_original": "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.",
    "warningsAndPrecautions_original": "Zoledronic Acid Injection is supplied as follows:\n\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Zoledronic Acid Injection (0.04 mg per mL)\n                           \n                           \n                              Package Factor\n                           \n                        \n                        \n                           25021-826-82\n\n                           4 mg per 100 mL in a Single-Dose Bag\n\n                           1 bag per carton\n\n                        \n                        \n                           25021-826-87\n\n                           4 mg per 100 mL in a Single-Dose Bag\n\n                           5 bags per carton",
    "adverseReactions_original": "Hypersensitivity reactions including cases of urticaria and angioedema, and cases of anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2)]."
}